| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
No direct pharmacological target; used as an internal standard. Unlabeled glutaric acid is an endogenous metabolite and intermediate in lysine and tryptophan catabolism. Affects pericyte contractility and migration, and is an indicator of glutaric aciduria type I.
|
|---|---|
| ln Vitro |
As a deuterated internal standard, Glutaric acid-d6 has no biological activity. Unlabeled glutaric acid is an endogenous metabolite and intermediate during lysine and tryptophan catabolism. It affects pericyte contractility and migration, and its presence can serve as an indicator of glutaric aciduria type I.
|
| ln Vivo |
No direct in vivo activity; used as a tracer and internal standard for quantification by NMR, GC-MS, or LC-MS. Used in metabolomics to quantify endogenous glutaric acid in plasma, urine, and CSF for diagnosis and monitoring of glutaric aciduria type I (GA1), caused by glutaryl-CoA dehydrogenase deficiency.
|
| Enzyme Assay |
(1) For LC-MS/MS: prepare calibration standards in blank matrix (1-1000 ng/mL) with fixed concentration of Glutaric acid-d6 (50-500 ng/mL). (2) Protein precipitation: add 3-5 volumes ice-cold acetonitrile/0.1% formic acid to 50-100 uL sample. (3) Evaporate supernatant, reconstitute in mobile phase. (4) Separate on C18 column, detect by ESI-MS/MS in negative ion mode: MRM m/z 131→87 (glutaric acid), m/z 137→93 (Glutaric acid-d6). (5) Use analyte/IS peak area ratio for quantification.
|
| Cell Assay |
No direct cellular assays; used as internal standard in metabolomics. (1) Seed cells of interest (e.g., hepatocytes, neurons). (2) Lyse cells with ice-cold methanol/water (4:1) containing Glutaric acid-d6 (1 ug/mL). (3) Add chloroform for phase separation, centrifuge, collect aqueous phase, evaporate, reconstitute. (4) Analyze by LC-MS/MS as described. (5) Quantify intracellular glutaric acid levels, normalize to protein concentration.
|
| Animal Protocol |
(1) Use 6-8 week old male C57BL/6 mice or Sprague-Dawley rats. (2) For GA1 model: use Gcdh-/- mice. (3) Collect plasma and 24-h urine. (4) To 50-100 uL sample, add Glutaric acid-d6 (50-500 ng/mL). (5) Protein precipitation with 3 vol ice-cold acetonitrile, centrifuge. (6) Analyze supernatant by LC-MS/MS. (7) Quantify glutaric acid, normalize urinary levels to creatinine. (8) For tissue distribution: collect liver, kidney, brain, homogenize in 80% methanol containing IS, centrifuge, analyze.
|
| ADME/Pharmacokinetics |
Stock solution in water, methanol, or 0.1% formic acid at 1-10 mg/mL. For LC-MS use, dilute to 0.5-50 ug/mL in mobile phase (0.1% formic acid in water/methanol). Storage: powder at -20degC for 3 years; solution at -20degC for 6 months, -80degC for 1 year. Solubility: water 50-100 mg/mL, ethanol, DMSO ≥30 mg/mL.
|
| Toxicity/Toxicokinetics |
Glutaric acid-d6 is non-toxic as it is a stable isotope-labeled endogenous metabolite used at trace levels. Unlabeled glutaric acid is an intermediate in lysine/tryptophan metabolism, normally present at low concentrations. At high concentrations (GA1), it is neurotoxic, causing striatal degeneration. However, the labeled compound is used at ng-ug/mL levels as analytical standard. Standard laboratory precautions apply.
|
| References |
|
| Additional Infomation |
Glutaric acid-d6 is a high-purity stable isotope-labeled internal standard (≥98% isotopic purity) for accurate quantification of glutaric acid by GC-MS or LC-MS. Glutaric acid is a key intermediate in L-lysine and L-tryptophan catabolism. Elevated urinary and plasma glutaric acid are diagnostic biomarkers for glutaric aciduria type I (GA1), a rare autosomal recessive disorder caused by glutaryl-CoA dehydrogenase deficiency, leading to neurological damage, macrocephaly, and dystonia. Not a drug; strictly for research and diagnostic use.
|
| Molecular Formula |
C5H2D6O4
|
|---|---|
| Molecular Weight |
138.15
|
| Exact Mass |
138.079
|
| CAS # |
154184-99-3
|
| Related CAS # |
Glutaric acid;110-94-1
|
| PubChem CID |
56845854
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
302.9±15.0 °C at 760 mmHg
|
| Flash Point |
151.2±16.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.477
|
| LogP |
-1.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])(C(=O)O)C([2H])([2H])C([2H])([2H])C(=O)O
|
| InChi Key |
JFCQEDHGNNZCLN-NMFSSPJFSA-N
|
| InChi Code |
InChI=1S/C5H8O4/c6-4(7)2-1-3-5(8)9/h1-3H2,(H,6,7)(H,8,9)/i1D2,2D2,3D2
|
| Chemical Name |
2,2,3,3,4,4-hexadeuteriopentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~125 mg/mL (~904.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (15.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (15.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (15.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2385 mL | 36.1925 mL | 72.3851 mL | |
| 5 mM | 1.4477 mL | 7.2385 mL | 14.4770 mL | |
| 10 mM | 0.7239 mL | 3.6193 mL | 7.2385 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
